Patent US5698531A successfully refreshed from Google Patents.
US5698531A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
Assignee: University of Michigan (System)
•
Filing: 1995-01-23
•
Granted: 1997-12-16
•
Expires: 2015-01-23
Abstract
Abstract A method for the direct treatment towards the specific sites of a disease is disclosed. This method is based on the delivery of proteins by catheterization to discrete blood vessel segments using genetically modified or normal cells or other vector systems. Endothelial cells expressing recombinant therapeutic agent or diagnostic proteins are situated on the walls of the blood vessel or in the tissue perfused by the vessel in a patient. This technique, provides for the transfer of cells or vectors and expression of recombinant genes in vivo and allows the introduction of proteins of therapeutic or diagnostic value for the treatment of diseases.
Inventors
- 👤 Elizabeth G. Nabel
- 👤 Gary J. Nabel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:44
CPC Classifications
A; A61; A61B; A61B17/00; A61B17/22; A61K; A61K31/00; A61K31/70; A61K39/00; A61K47/00; A61K47/50; A61K47/69; A61K47/6957; A61K48/00; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61L; A61L29/00; A61L29/14; A61L29/16; A61B2017/22038; A61B2017/22051; A61B2017/22054; A61B2017/22082; A61B2017/22084; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/258; A61L2300/60; A61L2300/62; A61L2300/626; A61L2300/64
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
42 words
A method of transfroming cells surrounding a blood vessel in a mammal, comprising introducing, by catheter, in said blood vessel a DNA sequence encoding a protein in an amount effective for transforming said cells, wherein said protein is expressed by said cells.
Claim 2
Independent Claim
42 words
A method of transfroming cells surrounding a blood vessel in a mammal, comprising introducing, by catheter, in said blood vessel a DNA sequence encoding a protein in an amount effective for transforming said cells, wherein said protein is expressed by said cells.
Claim 3
Dependent Claim
12 words
The method of claim 1 wherein said catheter is a balloon catheter.
Claim 4
Dependent Claim
13 words
The method of claim 1 wherein said catheter is a double balloon catheter.
Claim 5
Dependent Claim
13 words
The method of claim 1, wherein said protein is immunogenic to said patient.
Claim 6
Dependent Claim
11 words
The method of claim 1, wherein said protein induces cellular differentiation.
Claim 7
Dependent Claim
21 words
The method of claim 1, wherein said DNA sequence is obtained from a species which is the same as said mammal.
Claim 8
Dependent Claim
21 words
The method of claim 1, wherein said DNA sequence is obtained from a species different than the species of said mammal.
Claim 9
Dependent Claim
15 words
The method of claim 1, wherein said DNA sequence is administered in a viral vector.
Claim 10
Dependent Claim
15 words
The method of claim 1, wherein said DNA sequence is administered as a DNA/liposome complex.
Claim 11
Dependent Claim
51 words
The method of claim 1, wherein said DNA sequence is one member selected from the group consisting of Class I histocompatibility genes, Class II histocompatibility genes, genes encoding bacterial antigens, genes encoding viral glycoproteins having immunogenic properties, genes encoding minor histocompatibility antigens, genes encoding lysozymes or bovine serum albumin, and oncogenes.
Claim 12
Dependent Claim
62 words
The method of claim 1, wherein said DNA sequence is one member selected from the group consisting of DNA sequences encoding interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-6, interleukin-8, tumor necrosis factor-α, tumor necrosis factor-β1, tumor necrosis factor-β2, tumor necrosis factor-β3, soluble growth factors, recombinant antibodies to growth factors, recombinant antibodies to growth factor receptors, interferon α, interferon β, interferon γ, and adhesion molecules.
Claim 13
Dependent Claim
25 words
The method of claim 1, wherein said DNA sequence encodes one member selected from the group consisting of thymidine kinase, diphtheria toxin, and pertussis toxin.
Claim 14
Dependent Claim
46 words
The method according to claim 1, wherein said DNA sequence encodes an intracellular, secreted, or cell surface molecule which (1) is exogenous to said mammal and (2) is either immunogenic to said mammal; or induces rejection, regression or prevents progression of a tumor in said mammal.
Claim 15
Dependent Claim
11 words
The method of claim 1, wherein said DNA sequence encodes interleukin-2.
Claim 16
Dependent Claim
15 words
The method of claim 1, wherein said DNA sequence is a Class I histocompatibility gene.
References Cited (Backward Citations)
US4332893A
Cited
US4353888A
Cited
US4636195A
Cited
US4824436A
Cited
EP0273085A1
Cited
US4874746A
Cited
US5087617A
Cited
WO1990011092A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-12-15 | 2001-06-16 | 2001-12-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-12-15 | 2005-06-16 | 2005-12-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-12-15 | 2009-06-16 | 2009-12-16 | $7700.00 | Window Closed / Lapsed |